Friday, April 27, 2018

BRIEF-Thrombogenics Initiates Phase 2 Clinical Study For Treatment Of Diabetic Macular Edema

* THROMBOGENICS INITIATES PHASE 2 CLINICAL STUDY EVALUATING ANTI-PLGF (THR-317) IN COMBINATION WITH ANTI-VEGF (RANIBIZUMAB) FOR TREATMENT OF DIABETIC MACULAR EDEMA (DME)
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)